Combining SKY92 gene expression profiling and FISH (according to R2‐ISS) defines ultra‐high‐risk Multiple Myeloma

Documenti analoghi

• Clonal competition assays identify fitness signatures in cancer progression and resistance in multiple myeloma
  di: Larissa Haertle, et al.
  Pubblicazione: (2024)
• Endothelial dysfunction and proinflammatory state determine severe hematotoxicity and inferior outcome of CAR‐T therapy
  di: Lukas Scheller, et al.
  Pubblicazione: (2025)
• European Myeloma Network Group Consensus Statement on the use of next‐generation sequencing for prognostic stratification of newly diagnosed multiple myeloma
  di: Niccolò Bolli, et al.
  Pubblicazione: (2025)
• Sequencing BCMA‐ and GPRC5D‐targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network
  di: Niels W. C. J. van de Donk, et al.
  Pubblicazione: (2025)
• Evaluation of the R2‐ISS in real‐world patients with newly diagnosed multiple myeloma: A nationwide cohort study by the Korean Multiple Myeloma Working Party (KMM 2202)
  di: Hyungwoo Cho, et al.
  Pubblicazione: (2024)